| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10907425 | Experimental Hematology | 2010 | 14 Pages |
Abstract
Our data suggest that hESC-derived CD34+ cells have a potential for long-term in vivo endocrine cellular activity that could prove useful in regenerative medicine. Because the same cell population has previously been shown to contain hematopoietic potential, it could be used for the induction of immunological tolerance and bone marrow chimerism prior to cellular therapy for diabetes.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
A. Daisy Goodrich, Adel Ersek, Nicole M. Varain, Daria Groza, Mihai Cenariu, David S. Thain, Graca Almeida-Porada, Christopher D. Porada, Esmail D. Zanjani,